@prefix : <http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl> .

<http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl> rdf:type owl:Ontology ;
                                                                                owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                                rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/330444/"^^xsd:anyURI ;
                                                                                rdfs:label "Nintedanib and ischaemic colitis"^^xsd:Literal ;
                                                                                owl:versionInfo "draft-v0.95-20210520"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedBy
mp:supportedBy rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_10
:Administration_interval_10 rdf:type owl:NamedIndividual ,
                                     <http://www.w3.org/2006/time#DurationDescription> ;
                            <http://www.w3.org/2006/time#nominalPosition> "days" ;
                            <http://www.w3.org/2006/time#numericPosition> 1 ;
                            rdfs:label "Administration interval 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_1a
:Administration_interval_1a rdf:type owl:NamedIndividual ,
                                     <http://www.w3.org/2006/time#DurationDescription> ;
                            <http://www.w3.org/2006/time#nominalPosition> "days" ;
                            <http://www.w3.org/2006/time#numericDuration> 60 ;
                            <http://www.w3.org/2006/time#numericPosition> 1 ;
                            rdfs:label "Administration interval 1a" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_1b
:Administration_interval_1b rdf:type owl:NamedIndividual ,
                                     <http://www.w3.org/2006/time#DurationDescription> ;
                            <http://www.w3.org/2006/time#nominalPosition> "days" ;
                            <http://www.w3.org/2006/time#numericPosition> 1 ;
                            rdfs:label "Administration interval 1b" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_2a
:Administration_interval_2a rdf:type owl:NamedIndividual ,
                                     <http://www.w3.org/2006/time#DurationDescription> ;
                            <http://www.w3.org/2006/time#nominalPosition> "days" ;
                            <http://www.w3.org/2006/time#numericDuration> 330 ;
                            <http://www.w3.org/2006/time#numericPosition> 1 ;
                            rdfs:label "Administration interval 2a" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_2b
:Administration_interval_2b rdf:type owl:NamedIndividual ,
                                     <http://www.w3.org/2006/time#DurationDescription> ;
                            <http://www.w3.org/2006/time#nominalPosition> "days" ;
                            <http://www.w3.org/2006/time#numericDuration> 60 ;
                            <http://www.w3.org/2006/time#numericPosition> 1 ;
                            rdfs:label "Administration interval 2b" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_3
:Administration_interval_3 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "days" ;
                           <http://www.w3.org/2006/time#numericDuration> 300 ;
                           <http://www.w3.org/2006/time#numericPosition> 1 ;
                           rdfs:label "Administration interval 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_4
:Administration_interval_4 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "hours" ;
                           <http://www.w3.org/2006/time#numericPosition> 12 ;
                           rdfs:label "Administration interval 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_5
:Administration_interval_5 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "days" ;
                           <http://www.w3.org/2006/time#numericDuration> 150 ;
                           <http://www.w3.org/2006/time#numericPosition> 1 ;
                           rdfs:label "Administration interval 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_6
:Administration_interval_6 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "days" ;
                           <http://www.w3.org/2006/time#numericPosition> 1 ;
                           rdfs:label "Administration interval 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_7
:Administration_interval_7 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "days" ;
                           <http://www.w3.org/2006/time#numericPosition> 1 ;
                           rdfs:label "Administration interval 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Administration_interval_8
:Administration_interval_8 rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "days" ;
                           <http://www.w3.org/2006/time#numericPosition> 1 ;
                           rdfs:label "Administration interval 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Biologic_plausibility_for_nintedanib_and_ischaemic_colitis
:Biologic_plausibility_for_nintedanib_and_ischaemic_colitis rdf:type owl:NamedIndividual ,
                                                                     OpenPVSignal:Adverse_Effect_Mechanism ;
                                                            OpenPVSignal:is_part_of :Discussion_content ;
                                                            OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ,
                                                                                                  :intestinalIschaemia ;
                                                            OpenPVSignal:refers_to_drug :aflibercept ,
                                                                                        :bevacizumab ,
                                                                                        :nintedanib ,
                                                                                        :ranibizumab ,
                                                                                        :regorafenib ,
                                                                                        :sorafenib ,
                                                                                        :sunitinib ;
                                                            mp:references :Ref.6 ,
                                                                          :Ref.9 ;
                                                            OpenPVSignal:has_content "The biologic plausibility of an association between nintedanib and ischaemic colitis is based upon its inhibitory action of the VEGF-receptor. VEGF is a protein which mediates multiple functions within the vascular system, including endothelial cell proliferation as well as vascular permeability and vasodilation.6 Furthermore, VEGF mediates release of nitric oxide, and its inhibition causes vasoconstriction6" ;
                                                            rdfs:label "Biologic plausibility for nintedanib and ischaemic colitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Bradford_Hill_criteria
:Bradford_Hill_criteria rdf:type owl:NamedIndividual ,
                                 obo:OAE_0001197 ;
                        mp:references :Ref.10 ,
                                      :Ref.3 ,
                                      :Ref.5 ,
                                      :Ref.6 ,
                                      :Ref.7 ,
                                      :Ref.8 ,
                                      :Ref.9 ;
                        OpenPVSignal:has_content "The aim of this signal assessment is to argue for a potential causal relationship between nintedanib and ischaemic colitis. Five of the Bradford Hill criteria can be used to support this causal hypothesis, including strength of association, specificity, consistency, biological plausibility, and analogy.5 The strength of association has been explored with various approaches to analysing disproportionality in VigiBase. The initial drug-ADR combination identified by statistical screening of the database using the vigiRank algorithm for combination prioritisation was nintedanib-colitis. Colitis, being a general term meaning “inflammation of the colon”, provides no specificity as to the cause of the pathology. Within the MedDRA hierarchy, the PT colitis is located within an HLT colitis (excluding infectious); other PTs included within this HLT reflect the diversity of etiology of colitis: examples include autoimmune colitis, colitis ulcerative, necrotizing colitis, colitis ischaemic, colitis microscopic. Within this HLT, only two PTs were noted to exhibit significant disproportionality, colitis (IC025 0.89) and colitis ischaemic (IC025 0.32). To explore the potential to improve the specificity of the association, a subsequent search was performed utilising the SMQ ischaemic colitis (narrow); disproportionality analysis at this drug-SMQ level revealed an IC025 1.14. PTs included within this SMQ exhibiting increased disproportionality (observed > expected, although not all significantly enough to result in IC025 > 0) were large intestine perforation (IC025 1.48), large intestinal haemorrhage (IC025 -0.34), colitis ischemic (IC025 0.28), intestinal ischaemia (IC025 -0.92), gastrointestinal necrosis (IC025 -1.50), and intestinal infarction (IC025 -2.72). The clinical concepts of perforation and haemorrhage are already included as warnings in the product labelling. Consistency of the association is exhibited in the case series in the description of the clinical scenario of ischemic colitis, albeit being coded to various MedDRA PTs, from several countries throughout the world. The biologic plausibility of an association between nintedanib and ischaemic colitis is based upon its inhibitory action of the VEGF-receptor. VEGF is a protein which mediates multiple functions within the vascular system, including endothelial cell proliferation as well as vascular permeability and vasodilation.6 A mouse model has shown that inhibition of VEGF signalling resulted in regression of capillaries of intestinal villi7 and it has been hypothesized that VEGF inhibition contributes directly to GI perforation by inducing regression of normal blood vessels in the GI tract8 (presumably via an intermediate step of ischaemia). Furthermore, VEGF mediates release of nitric oxide, and its inhibition causes vasoconstriction6; indeed, hypertension is a well-characterised ADR for all anti-VEGF agents. Additionally, the labelling for anti-VEGF agents include a warning for arterial thromboembolism; the label for nintedanib specifically cautions for acute myocardial ischaemia in the treatment in patients at higher cardiovascular risk including known coronary artery disease.3 Given its inhibitory effect on the VEGF receptor, the ADR profile for nintedanib can be considered analogous to other anti-angiogenic agents which antagonise VEGF (aflibercept, bevacizumab) or inhibit the VEGF-receptor (regorafenib, sorafenib). Indeed, the labels for all products contained harmonised wording regarding the risk of gastrointestinal perforation, and all also lack the inclusion of ischaemic colitis. However, literature review reveals case reports of ischaemic colitis with other VEGF-receptor antagonists, specifically, aflibercept (intravitreal administration)9 and bevacuzimab,10 both of which were administered intravitreally. Data mining within VigiBase reveals evidence of disproportional reporting of MedDRA PT within the “ischaemic colitis” SMQ for a number of other anti-angiogenic agents (bevacizumab: intestinal ischaemia IC025 2.23; colitis ischaemic IC025 2.24; aflibercept: colitis ischaemic IC025 0.62; midostaurin: intestinal ischaemia IC025 0.38; ranibizumab: intestinal ischaemia IC025 0.36; sunitinib: intestinal ischaemia IC025 0.22; sorafenib: colitis ischaemic IC025 0.18)." ;
                        rdfs:label "Bradford Hill criteria" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_1
:Case_Info_1 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient1 ;
             OpenPVSignal:has_content "55 kg, 159 cm" ;
             rdfs:label "Case Info 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_2
:Case_Info_2 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient2 ;
             OpenPVSignal:has_content "62.9 kg, 165 cm" ;
             rdfs:label "Case Info 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_5
:Case_Info_5 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient5 ;
             OpenPVSignal:has_content "36 kg, 153 cm" ,
                                      "History of hyperlipidemia, osteoporosis, gastroesophageal reflux disease, venous thrombosis, constipation, insomnia, chronic gastritis, breast cancer" ;
             rdfs:label "Case Info 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_6
:Case_Info_6 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient6 ;
             OpenPVSignal:has_content "185 cm" ,
                                      """Patient presented with abdominal pain 27 days after initiation on nintedanib. Admitted to hospital, diagnosed with ischaemic colitis (grade 2), and treated with mesalazin. Five days later, the patient experienced obstipation. Ten days later, the patient had stomach pain (grade 3), acute mesenteric ischemia (grade 4), 
thromboembolic event (grade 4), and peripheral ischemia (grade 3). Had thromobectomy of arteria mesenterica superior, explorative laparotomy and small intestinal segment resection. Hospitalisation complicated by wound healing disorder which led to cardiovascular failure, sepsis and death.""" ;
             rdfs:label "Case Info 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_8
:Case_Info_8 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient8 ;
             OpenPVSignal:has_content "Surgery preparation of colon descendens, sigmoideum and upper rectum with intense and distinct ischemic necrosis of gut wall, inclusion of max. 2.3 cm polyp, without evidence of vital mucosa. Beside a 0.9 cm in sano resected tubular adenoma with slight intraepithelial neoplasia (low-grade adenoma following WHO-classification). Transmural hemorraghic necrosis (reaching out up to the resection area) of gut wall without inflammation, as appropriate for ischemia." ;
             rdfs:label "Case Info 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_Info_9
:Case_Info_9 rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Case_Report_Information ;
             OpenPVSignal:refers_to_patient :Patient9 ;
             OpenPVSignal:has_content "69 kg" ;
             rdfs:label "Case Info 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Case_reports_of_ischaemic_cilitis
:Case_reports_of_ischaemic_cilitis rdf:type owl:NamedIndividual ,
                                            obo:OAE_0001197 ;
                                   OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                   OpenPVSignal:refers_to_drug :aflibercept ,
                                                               :bevacizumab ;
                                   mp:references :Ref.10 ,
                                                 :Ref.9 ;
                                   OpenPVSignal:has_content """However, literature review reveals case reports of ischaemic colitis with 
other VEGF-receptor antagonists, specifically, aflibercept (intravitreal administration)9 and bevacuzimab,10 both of which were administered intravitreally.""" ;
                                   rdfs:label "Case reports of ischaemic cilitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Conclusion_content
:Conclusion_content rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Conclusion ;
                    OpenPVSignal:has_content """Screening of VigiBase has identified a signal of disproportional reporting of colitis with nintedanib, a small molecule tyrosine-kinase inhibitor. Given that nintedanib blocks VEGF receptors, the initial signal was further explored in VigiBase and refined to the more specific clinical phenomenon of “ischaemic colitis”. The case series supporting this signal consists of 10 cases, captured under several MedDRA PTs including “colitis”, “colitis ischaemic”, “intestinal ischaemia” and “intestinal infarction”.
Assessment of the signal demonstrated the data support of the Bradford Hill criteria has resulted in a conclusion of a reasonable possibility of a causal relationship between nintedanib and ischaemic colitis.
It appears prudent to consider the addition of ischaemic colitis to the product labelling for nintedanib. Furthermore, given that the most commonly occurring gastrointestinal adverse reaction is diarrhoea, which can be a symptom of ischaemic colitis, it could be important to inform health care providers to rule out ischaemia prior to the recommended symptomatic treatment of diarrhoea with loperamide.""" ;
                    rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Discussion_content
:Discussion_content rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Conclusion ;
                    mp:references :Ref.10 ,
                                  :Ref.11 ,
                                  :Ref.12 ,
                                  :Ref.13 ,
                                  :Ref.14 ,
                                  :Ref.3 ,
                                  :Ref.5 ,
                                  :Ref.6 ,
                                  :Ref.7 ,
                                  :Ref.8 ,
                                  :Ref.9 ;
                    OpenPVSignal:has_content """The aim of this signal assessment is to argue for a potential causal relationship between nintedanib and ischaemic colitis. Five of the Bradford Hill criteria can be used to support this causal hypothesis, including strength of association, specificity, consistency, biological plausibility, and analogy.5
The strength of association has been explored with various approaches to analysing disproportionality in VigiBase. The initial drug-ADR combination identified by statistical screening of the database using the vigiRank algorithm for combination prioritisation was nintedanib-colitis. Colitis, being a general term meaning “inflammation of the colon”, provides no specificity as to the cause of the pathology. Within the MedDRA hierarchy, the PT colitis is located within an HLT colitis (excluding infectious); other PTs included within this HLT reflect the diversity of etiology of colitis: examples include autoimmune colitis, colitis ulcerative, necrotizing colitis, colitis ischaemic, colitis microscopic. Within this HLT, only two PTs were noted to exhibit significant disproportionality, colitis (IC025 0.89) and colitis ischaemic (IC025 0.32). To explore the potential to improve the specificity of the association, a subsequent search was performed utilising the SMQ ischaemic colitis (narrow); disproportionality analysis at this drug- SMQ level revealed an IC025 1.14. PTs included within this SMQ exhibiting increased disproportionality (observed > expected, although not all significantly enough to result in IC025 > 0) were large intestine perforation (IC025 1.48), large intestinal haemorrhage (IC025 -0.34), colitis ischemic (IC025 0.28), intestinal ischaemia (IC025
-0.92), gastrointestinal necrosis (IC025 -1.50), and intestinal infarction (IC025 -2.72). The clinical concepts of perforation and haemorrhage are already included as warnings in the product labelling.
Consistency of the association is exhibited in the case series in the description of the clinical scenario of ischemic colitis, albeit being coded to various MedDRA PTs, from several countries throughout the world.
The biologic plausibility of an association between nintedanib and ischaemic colitis is based upon its inhibitory action of the VEGF-receptor. VEGF is a protein which mediates multiple functions within the vascular system, including endothelial cell proliferation as well as vascular permeability and vasodilation.6 A mouse model has shown that inhibition of VEGF signalling resulted in regression of capillaries of intestinal villi7 and it has been hypothesized that VEGF inhibition contributes directly to GI perforation by inducing regression of normal blood vessels in the GI tract8 (presumably via an intermediate step of ischaemia).
Furthermore, VEGF mediates release of nitric oxide,
and its inhibition causes vasoconstriction6; indeed, hypertension is a well-characterised ADR for all anti-VEGF agents. Additionally, the labelling for anti-VEGF agents include a warning for arterial thromboembolism; the label for nintedanib specifically cautions for acute myocardial ischaemia
in the treatment in patients at higher cardiovascular risk including known coronary artery disease.3
Given its inhibitory effect on the VEGF receptor, the ADR profile for nintedanib can be considered analogous to other anti-angiogenic agents which antagonise VEGF (aflibercept, bevacizumab) or inhibit the VEGF-receptor (regorafenib, sorafenib). Indeed, the labels for all products contained harmonised wording regarding the risk of gastrointestinal perforation, and all also lack the inclusion of ischaemic colitis. However, literature review reveals case reports of ischaemic colitis with other VEGF-receptor antagonists, specifically, aflibercept (intravitreal administration)9 and bevacuzimab,10 both of which were administered intravitreally. Data mining within VigiBase reveals evidence of disproportional reporting of MedDRA PT within the “ischaemic colitis” SMQ for a number of other anti-angiogenic agents (bevacizumab: intestinal ischaemia IC025 2.23; colitis ischaemic IC025 2.24; aflibercept: colitis ischaemic IC025 0.62; midostaurin: intestinal ischaemia IC025 0.38; ranibizumab: intestinal ischaemia IC025 0.36; sunitinib: intestinal ischaemia IC025 0.22; sorafenib: colitis ischaemic IC025 0.18).
Given that both diarrhoea and gastrointestinal perforation are included in the label, it is relevant to consider the possibility that gastrointestinal ischaemia is the underlying pathology for each of these “known” ADRs. Small perturbations of blood flow by VEGF inhibition can lead to rapid metabolic changes in the intestinal mucosa characteristic of hypoxia and ischaemia.11 Epithelial hypoxia is clinically associated with diarrhoea,12 and changes in the bowel mucosa are consistent with ischaemic colitis.13 A small study of 10 patients aimed to examine the underlying pathophysiologic mechanism of diarrhoea. Sigmoidoscopy revealed no evidence of ischaemia in any of the 10 subjects; however, gastroduodenoscopy revealed mucosal abnormalities in 8 patients.14 There is better knowledge on the role of ischaemia in gastrointestinal perforation, as perforation is a known complication of gastrointestinal ischaemia.
However, the labelling currently describes other risk
factors for perforation such as concomitant corticosteroid use and prior history of abdominal surgery without mention of gastrointestinal ischaemia.
Taking all of the presented evidence together, it is considered that there is a reasonable possibility that nintedanib can cause ischaemic colitis.""" ;
                    rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_1
:Dosage_1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_1a ;
          OpenPVSignal:has_content "300 mg qd x 2 months" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 300 ;
          OpenPVSignal:refers_to_dose_value "300 mg" ;
          rdfs:label "Dosage 1a" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_10
:Dosage_10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Dosage ;
           OpenPVSignal:refers_to_drug :nintedanib ;
           OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_10 ;
           OpenPVSignal:has_content "400 mg once per day" ;
           OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
           OpenPVSignal:has_value 400 ;
           OpenPVSignal:refers_to_dose_value "400 mg" ;
           rdfs:label "Dosage 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_1b
:Dosage_1b rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Dosage ;
           OpenPVSignal:refers_to_drug :nintedanib ;
           OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_1b ;
           OpenPVSignal:has_content "followed by 200 mg qd (duration unknown)" ;
           OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
           OpenPVSignal:has_value 200 ;
           OpenPVSignal:refers_to_dose_value "200 mg" ;
           rdfs:label "Dosage 1b" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_2
:Dosage_2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_2a ;
          OpenPVSignal:has_content "300 mg qd x 11 months" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 300 ;
          OpenPVSignal:refers_to_dose_value "300 mg" ;
          rdfs:label "Dosage 2a" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_2b
:Dosage_2b rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Dosage ;
           OpenPVSignal:refers_to_drug :nintedanib ;
           OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_2b ;
           OpenPVSignal:has_content "200 mg x qd x 2 months" ;
           OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
           OpenPVSignal:has_value 200 ;
           OpenPVSignal:refers_to_dose_value "200 mg" ;
           rdfs:label "Dosage 2b" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_3
:Dosage_3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_3 ;
          OpenPVSignal:has_content "300 mg qd x 10 months" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 300 ;
          OpenPVSignal:refers_to_dose_value "300 mg" ;
          rdfs:label "Dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_4
:Dosage_4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_4 ;
          OpenPVSignal:has_content "150 mg 2 per day" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 150 ;
          OpenPVSignal:refers_to_dose_value "150 mg" ;
          rdfs:label "Dosage 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_5
:Dosage_5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_5 ;
          OpenPVSignal:has_content "200 mg qd x 5 months" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 200 ;
          OpenPVSignal:refers_to_dose_value "200 mg" ;
          rdfs:label "Dosage 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_6
:Dosage_6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_6 ;
          OpenPVSignal:has_content "400 mg per day" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 400 ;
          OpenPVSignal:refers_to_dose_value "400 mg" ;
          rdfs:label "Dosage 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_7
:Dosage_7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_7 ;
          OpenPVSignal:has_content "2 DF per day" ;
          OpenPVSignal:has_dosage_unit "DF"^^xsd:string ;
          OpenPVSignal:has_value 2 ;
          OpenPVSignal:refers_to_dose_value "2 DF" ;
          rdfs:label "Dosage 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Dosage_8
:Dosage_8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          OpenPVSignal:refers_to_interval_between_administrations :Administration_interval_8 ;
          OpenPVSignal:has_content "400 mg per day" ;
          OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
          OpenPVSignal:has_value 400 ;
          OpenPVSignal:refers_to_dose_value "400 mg" ;
          rdfs:label "Dosage 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Epithelial_hypoxia_in_diarrhoea_pathobiology
:Epithelial_hypoxia_in_diarrhoea_pathobiology rdf:type owl:NamedIndividual ,
                                                       obo:OAE_0001197 ,
                                                       OpenPVSignal:Adverse_Effect_Mechanism ;
                                              OpenPVSignal:is_part_of :Discussion_content ;
                                              OpenPVSignal:refers_to_adverse_effect :diarrhoea ,
                                                                                    :gastrointestinalPerforation ,
                                                                                    :hypoxia ,
                                                                                    :ischemia ;
                                              mp:references :Ref.10 ,
                                                            :Ref.11 ,
                                                            :Ref.12 ,
                                                            :Ref.13 ;
                                              OpenPVSignal:has_content "Given that both diarrhoea and gastrointestinal perforation are included in the label, it is relevant to consider the possibility that gastrointestinal ischaemia is the underlying pathology for each of these “known” ADRs. Small perturbations of blood flow by VEGF inhibition can lead to rapid metabolic changes in the intestinal mucosa characteristic of hypoxia and ischaemia.11 Epithelial hypoxia is clinically associated with diarrhoea,12 and changes in the bowel mucosa are consistent with ischaemic colitis.13" ;
                                              rdfs:label "Epithelial hypoxia and ischaemia in diarrhoea and gastrointestinal perforation" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Idiopathic_pulmonary_fibrosis_pathophysiology
:Idiopathic_pulmonary_fibrosis_pathophysiology rdf:type owl:NamedIndividual ,
                                                        OpenPVSignal:Free_text_reporting_element ;
                                               OpenPVSignal:is_part_of :Introduction_content ;
                                               OpenPVSignal:refers_to_adverse_effect :idiopathicPulmonaryFibrosis ;
                                               mp:references :Ref.1 ;
                                               OpenPVSignal:has_content "Idiopathic pulmonary fibrosis (IPF) is a rare disease of unknown aetiology that is characterized by an excess of fibroblasts, leading to fibrosis of the interstitium of the lung. The fibrosis is a progressive process, leading to decreased lung volume and ultimately, respiratory failure. Median survival, as described across a range of studies, is only two to five years after diagnosis. IPF is an uncommon disease with a prevalence of 3 per 10,000, and it is most prevalent in middle-aged and elderly patients.1" ;
                                               rdfs:label "pathophysiology of idiopathic pulmonary fibrosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Introduction_content
:Introduction_content rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Introduction ;
                      mp:references :Ref.1 ,
                                    :Ref.2 ;
                      OpenPVSignal:has_content """The drug
Nintedanib is a small molecule receptor tyrosine kinase inhibitor (TKI) blocking vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3) and platelet- derived growth factor receptors (PDGFR) α and β kinase activity. In pre-clinical studies, nintedanib was found to inhibit the proliferation and transformation of human lung fibroblasts and showed antifibrotic and anti-inflammatory activity in two animal models of pulmonary fibrosis.1
Idiopathic pulmonary fibrosis (IPF) is a rare disease of unknown aetiology that is characterized by an excess of fibroblasts, leading to fibrosis of the interstitium of the lung. The fibrosis is a progressive process, leading to decreased lung volume and ultimately, respiratory failure. Median survival, as described across a range of studies, is only two to five years after diagnosis. IPF is an uncommon disease with a prevalence of 3 per 10,000, and it is most prevalent in middle-aged and elderly patients.1
Nintedanib was licensed for use in the treatment of IPF by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) in 2014. In two pivotal clinical trials, benefit with nintedanib was measured by a reduction in the decline of a measure of lung function, the forced vital capacity (FVC), by approximately 94 mL/year and 125 mL/year respectively. It has also been licensed by the EMA for use in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.1 Additionally, given its anti-angiogenic effects as a VEGFR-inhibitor, it is being tested in clinical trials for other oncology indications.

Ischaemic colitis
Ischaemic colitis is a condition caused by insufficient blood flow to the large intestine which results in mucosal ulceration, inflammation and haemorrhage. Causes can be either physiological (hypotension, secondary to embolus/thrombosis) or iatrogenic (secondary to medicines, surgery).
Ischaemic colitis clinically manifests with diarrhoea, colicky abdominal pain, and rectal bleeding. It can be difficult for clinicians to differentiate ischaemic colitis from infective and inflammatory colitis. With its high mortality rate, patients with ischaemic colitis should be recognised quickly, as colonoscopic evaluation is recommended within 48 hours of symptom onset. Colonoscopy can distinguish those cases that may be treated with conservative management from those that require emergency resection. The complications which can arise from ischaemic colitis include obstruction, necrosis, and perforation.2""" ;
                      rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ischaemic_colitis_pathobiology
:Ischaemic_colitis_pathobiology rdf:type owl:NamedIndividual ,
                                         obo:OAE_0000005 ;
                                rdfs:label "Ischaemic colitis pathobiology" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Labelling_and_literature
:Labelling_and_literature rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Literature_information ;
                          mp:references :Ref.3 ,
                                        :Ref.4 ;
                          OpenPVSignal:has_content """Product labelling for nintedanib includes warnings for diarrhoea and gastrointestinal perforation in section 4.4 of the Summary of Product Characteristics. There is also information regarding management options for serious cases of diarrhoea including hydration, anti-diarrhoeal products, and dose reduction and information regarding potential risk factors for gastrointestinal perforation, such as previous abdominal surgery or peptic ulceration, and diverticular disease and concomitant use of corticosteroids or NSAIDs. Included in the list of ADRs in section 4.8 are nausea, vomiting, diarrhoea, abdominal pain and pancreatitis.3
Within the risk management plan were the identified risks of diarrhoea and liver function abnormalities as important identified risks and “perforation” as an important potential risk; there were no planned post-authorisation safety studies to further characterise any risks for the gastrointestinal system.4""" ;
                          rdfs:label "Labelling and literature" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Labelling_for_anti-VEGF_agents
:Labelling_for_anti-VEGF_agents rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Structured_Product_Labels_information ,
                                         OpenPVSignal:Warning_Information ;
                                OpenPVSignal:refers_to_adverse_effect :gastrointestinalPerforation ;
                                OpenPVSignal:refers_to_drug :aflibercept ,
                                                            :bevacizumab ,
                                                            :regorafenib ,
                                                            :sorafenib ;
                                OpenPVSignal:has_content "Given its inhibitory effect on the VEGF receptor, the ADR profile for nintedanib can be considered analogous to other anti-angiogenic agents which antagonise VEGF (aflibercept, bevacizumab) or inhibit the VEGF-receptor (regorafenib, sorafenib). Indeed, the labels for all products contained harmonised wording regarding the risk of gastrointestinal perforation, and all also lack the inclusion of ischaemic colitis." ;
                                rdfs:label "Labelling for anti-VEGF agents" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Mechanism_of_nintedanib
:Mechanism_of_nintedanib rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Mechanism ;
                         mp:references :Ref.1 ;
                         OpenPVSignal:has_content "Nintedanib is a small molecule receptor tyrosine kinase inhibitor (TKI) blocking vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3) and platelet- derived growth factor receptors (PDGFR) α and β kinase activity. In pre-clinical studies, nintedanib was found to inhibit the proliferation and transformation of human lung fibroblasts and showed antifibrotic and anti-inflammatory activity in two animal models of pulmonary fibrosis.1" ;
                         rdfs:label "Mechanism of nintedanib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndColitisischaemic-IC
:NintedanibAndColitisischaemic-IC rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                  OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                  OpenPVSignal:refers_to_drug :nintedanib ;
                                  OpenPVSignal:has_expected_count "1.56"^^xsd:float ;
                                  OpenPVSignal:has_value 1.65 ;
                                  OpenPVSignal:refers_to_number_of_reports 6 ;
                                  rdfs:label "Nintedanib and colitis ischaemic-IC" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndColitisischaemic-IC025
:NintedanibAndColitisischaemic-IC025 rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                     OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                     OpenPVSignal:refers_to_drug :nintedanib ;
                                     OpenPVSignal:refers_to_information_component :NintedanibAndColitisischaemic-IC ;
                                     OpenPVSignal:has_value 0.28 ;
                                     rdfs:label "nintedanib and colitis ischaemic-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndColitisischaemic-Nexpected
:NintedanibAndColitisischaemic-Nexpected rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Statistical_Entity ;
                                         OpenPVSignal:has_value 1.56 ;
                                         rdfs:label "Nintedanib and colitis ischaemic-Nexpected" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndColitisischaemic-Nobserved
:NintedanibAndColitisischaemic-Nobserved rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Statistical_Entity ;
                                         OpenPVSignal:has_value 6 ;
                                         rdfs:label "Nintedanib and colitis ischaemic-Nobserved" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalinfarction-IC
:NintedanibAndIntestinalinfarction-IC rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                      OpenPVSignal:refers_to_adverse_effect :intestinalInfarction ;
                                      OpenPVSignal:refers_to_drug :nintedanib ;
                                      OpenPVSignal:has_expected_count "0.21"^^xsd:float ;
                                      OpenPVSignal:has_value 1.07 ;
                                      OpenPVSignal:refers_to_number_of_reports 1 ;
                                      rdfs:label "Nintedanib and intestinal infarction-IC" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalinfarction-IC025
:NintedanibAndIntestinalinfarction-IC025 rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                         OpenPVSignal:refers_to_adverse_effect :intestinalInfarction ;
                                         OpenPVSignal:refers_to_drug :nintedanib ;
                                         OpenPVSignal:refers_to_information_component :NintedanibAndIntestinalinfarction-IC ;
                                         OpenPVSignal:has_value -2.72 ;
                                         rdfs:label "nintedanib and intestinal infarction-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalinfarction-Nexpected
:NintedanibAndIntestinalinfarction-Nexpected rdf:type owl:NamedIndividual ,
                                                      OpenPVSignal:Statistical_Entity ;
                                             OpenPVSignal:has_value 0.21 ;
                                             rdfs:label "Nintedanib and intestinal infarction-Nexpected" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalinfarction-Nobserved
:NintedanibAndIntestinalinfarction-Nobserved rdf:type owl:NamedIndividual ,
                                                      OpenPVSignal:Statistical_Entity ;
                                             OpenPVSignal:has_value 1 ;
                                             rdfs:label "Nintedanib and intestinal infarction-Nobserved" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalischaemia-IC
:NintedanibAndIntestinalischaemia-IC rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                     OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                     OpenPVSignal:refers_to_drug :nintedanib ;
                                     OpenPVSignal:has_expected_count "1.1"^^xsd:float ;
                                     OpenPVSignal:has_value 1.13 ;
                                     OpenPVSignal:refers_to_number_of_reports 3 ;
                                     rdfs:label "Nintedanib and Intestinal ischaemia-IC" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalischaemia-IC025
:NintedanibAndIntestinalischaemia-IC025 rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                        OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                        OpenPVSignal:refers_to_drug :nintedanib ;
                                        OpenPVSignal:refers_to_information_component :NintedanibAndIntestinalischaemia-IC ;
                                        OpenPVSignal:has_value -0.92 ;
                                        rdfs:label "nintedanib and Intestinal ischaemia-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalischaemia-Nexpected
:NintedanibAndIntestinalischaemia-Nexpected rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Statistical_Entity ;
                                            OpenPVSignal:has_value 1.1 ;
                                            rdfs:label "Nintedanib and Intestinal ischaemia-Nexpected" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIntestinalischaemia-Nobserved
:NintedanibAndIntestinalischaemia-Nobserved rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Statistical_Entity ;
                                            OpenPVSignal:has_value 3 ;
                                            rdfs:label "Nintedanib and Intestinal ischaemia-Nobserved" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndIschaemicColitisSMQ-IC
:NintedanibAndIschaemicColitisSMQ-IC rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                     OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ischaemic_colitis_(SMQ)> ;
                                     OpenPVSignal:refers_to_drug :nintedanib ;
                                     OpenPVSignal:has_value 1.77 ;
                                     rdfs:label "Nintedanib and Ischaemic colitis SMQ-IC" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndcolitis-IC
:NintedanibAndcolitis-IC rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                         OpenPVSignal:refers_to_adverse_effect :colitis ;
                         OpenPVSignal:refers_to_drug :nintedanib ;
                         OpenPVSignal:has_expected_count "9.23"^^xsd:float ;
                         OpenPVSignal:has_value 1.65 ;
                         OpenPVSignal:refers_to_number_of_reports 30 ;
                         rdfs:label "Nintedanib and colitis-IC" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndcolitis-IC50
:NintedanibAndcolitis-IC50 rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                           OpenPVSignal:refers_to_adverse_effect :colitis ;
                           OpenPVSignal:refers_to_drug :nintedanib ;
                           OpenPVSignal:refers_to_information_component :NintedanibAndcolitis-IC ;
                           OpenPVSignal:has_value 1.09 ;
                           rdfs:label "Nintedanib and colitis-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndcolitis-Nexpected
:NintedanibAndcolitis-Nexpected rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Statistical_Entity ;
                                OpenPVSignal:has_value 9.23 ;
                                rdfs:label "Nintedanib and colitis-Nexpected" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#NintedanibAndcolitis-Nobserved
:NintedanibAndcolitis-Nobserved rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Statistical_Entity ;
                                OpenPVSignal:has_value 30 ;
                                rdfs:label "Nintedanib and colitis-Nobserved" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Nintedanib_and_Ischaemic_colitis_SMQ-IC025
:Nintedanib_and_Ischaemic_colitis_SMQ-IC025 rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                            OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ischaemic_colitis_(SMQ)> ;
                                            OpenPVSignal:refers_to_drug :nintedanib ;
                                            OpenPVSignal:refers_to_information_component :NintedanibAndIschaemicColitisSMQ-IC ;
                                            OpenPVSignal:has_value 1.14 ;
                                            rdfs:label "Nintedanib and Ischaemic colitis SMQ-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Nintedanib_and_ischaemic__colitis
:Nintedanib_and_ischaemic__colitis rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                   OpenPVSignal:refers_to_author :Rebecca_E_Chandler ;
                                   OpenPVSignal:refers_to_signal :pvSignal ;
                                   mp:publishedBy :Uppsala_Monitoring_Centre ;
                                   OpenPVSignal:has_creation_date "01/12/2019" ;
                                   OpenPVSignal:has_overall_conclusion "causal association most probable" ;
                                   rdfs:label "Nintedanib and ischaemic  colitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Overall_Time_to_onset
:Overall_Time_to_onset rdf:type owl:NamedIndividual ,
                                <http://www.w3.org/2006/time#DurationDescription> ;
                       OpenPVSignal:has_content "Time to onset ranged from three days to five months." ;
                       rdfs:label "Overall Time to onset" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 78 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 57 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 74 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 65 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 77 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 77 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 53 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 56 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 74 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Product_labelling_for_nintedanib
:Product_labelling_for_nintedanib rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Structured_Product_Labels_information ,
                                           OpenPVSignal:Warning_Information ;
                                  OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                                        :acuteMyocardialIschaemia ,
                                                                        :diarrhoea ,
                                                                        :gastrointestinalPerforation ,
                                                                        :nausea ,
                                                                        :pancreatitis ,
                                                                        :vomiting ;
                                  OpenPVSignal:refers_to_drug :nintedanib ;
                                  mp:references :Ref.3 ;
                                  OpenPVSignal:has_content """Product labelling for nintedanib includes warnings for diarrhoea and gastrointestinal perforation in section 4.4 of the Summary of Product Characteristics. There is also information regarding management options for serious cases of diarrhoea including hydration, anti-diarrhoeal products, and dose reduction and information regarding potential risk factors for gastrointestinal perforation, such as previous abdominal surgery or peptic ulceration, and diverticular disease and concomitant use of corticosteroids or NSAIDs. Included in the list of ADRs in section 4.8 are nausea, vomiting, diarrhoea, abdominal pain and pancreatitis.3
 the label for nintedanib 
specifically cautions for acute myocardial ischaemia in the treatment in patients at higher cardiovascular risk including known coronary artery disease.3""" ;
                                  rdfs:label "Product labelling for nintedanib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Rebecca_E_Chandler
:Rebecca_E_Chandler rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Author ;
                    OpenPVSignal:has_affiliation "Uppsala Monitoring Centre" ;
                    OpenPVSignal:has_first_name "Rebecca" ;
                    OpenPVSignal:has_last_name "Chandler" ;
                    rdfs:label "Rebecca E Chandler" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Assessment report Ofev Procedure No. EMEA/H/C/003821/0000. London: European Medicines Agency; 2015. Available from: https://www.ema.europa.eu/en/documents/as sessment-report/ofev-epar-public-assessment- report_en.pdf. Accessed March 2019" ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Onoda Y, Shiba T, Hori Y, Maeno T, Takahashi M. Two cases of acute abdomen after an intravitreal injection of bevacizumab. Case Rep Ophthalmol. 2015;6(1):110‐4." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Zheng W, Kuhlicke J, Jackel K. Hypoxia inducible factor-1 (HIF-1)-mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium. FASEB J. 2009;23:204-13." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Sreenarasimhaiah J. Diagnosis and management of ischemic colitis. Curr Gastroenterol Rep. 2005;7:421-6." ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006;64:1295-8." ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Boers-Sonderen M, Mulder S, Nagtegaal ID, Derikx L, Wanten G, Mulders P, et al. A biopsy- guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor. Journal of Clinical Oncology. 2015;33(15) Suppl:e15596." ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Trotter JM, Hunt L, Peter MB. Ischaemic colitis. BMJ 2016;355:i6600" ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Ofev: EPAR Product information. Available from: https://www.ema.europa.eu/en/documents/pr oduct-information/ofev-epar-product- information_en.pdf. Accessed March 2019." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Ofev: EPAR Risk management plan summary. Available from: https://www.ema.europa.eu/en/documents/rm p-summary/ofev-epar-risk-management-plan- summary_en.pdf. Accessed March 2019." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Perrio M, Voss S, Shakir SA. Application of the Bradford Hill Criteria to Assess the Causality Cisapride-Induced Arrythmia. Drug Safety. 2007;30(4):333-46." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Ellis LM, Hicklin DL. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer. 2008;8:579-91." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Kamba T, Tam BY, Hashizume H, et al. VEGF- dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol. 2006;290(2):H560–H5766." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860–9." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Batteux B, Gras V, Mahboud Y, Liabeuf S, Bennis Y, Masmoudi K. Ischemic colitis associated with intravitreal administration of aflibercept: a first case report. Br J Clin Pharmacol. 2019 April;85(4):845-8." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_potential_confounding_factor :corticosteroids ;
         OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
         OpenPVSignal:refers_to_concomitant_drug :acetylcysteine ,
                                                 :dimemorfan ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_1 ;
         OpenPVSignal:refers_to_secondary_suspect_drug :prednisolone ;
         OpenPVSignal:time_to_onset :TTO1 ;
         OpenPVSignal:has_reporter_type "study" ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :anorexia ,
                                                :colitis ,
                                                :diarrhoea ,
                                                :mucositis ,
                                                :nausea ,
                                                :respiratoryFailure ,
                                                :vomiting ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :fluvastatin ,
                                                  :glycerylTrinitrate ,
                                                  :ipratropium ,
                                                  :lormetazepam ,
                                                  :metamizole ,
                                                  :omeprazole ,
                                                  :torasemide ;
          OpenPVSignal:refers_to_patient :Patient10 ;
          OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
          OpenPVSignal:refers_to_reported_drug_usage :Usage_10 ;
          OpenPVSignal:time_to_onset :TTO10 ;
          OpenPVSignal:has_reporter_type "clinical trial report" ;
          OpenPVSignal:refers_to_outcome_after_action "irrelevant death" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_potential_confounding_factor :hyperlipidemia ;
         OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ,
                                               :pneumoniaBacterial ;
         OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                 :atorvastatin ,
                                                 :irbesartan ,
                                                 :trichlormethiazide ,
                                                 :vonoprazan ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_2 ;
         OpenPVSignal:time_to_onset :TTO2 ;
         OpenPVSignal:has_reporter_type "study" ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
         OpenPVSignal:refers_to_concomitant_drug :alfacalcidol ,
                                                 :ascorbicAcid ,
                                                 :levothyroxine ,
                                                 :minodronicAcid ,
                                                 :pantothenicAcid ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_3 ;
         OpenPVSignal:time_to_onset :TTO3 ;
         OpenPVSignal:has_reporter_type "study" ;
         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :abnormalLossOfWeight ,
                                               :colitis_ischaemic ,
                                               :decreasedAppetite ,
                                               :diarrhoea ,
                                               :nausea ,
                                               :septicShock ,
                                               :vomiting ;
         OpenPVSignal:refers_to_concomitant_drug :insulin ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_4 ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_potential_confounding_factor :corticosteroids ,
                                                       :hyperlipidemia ;
         OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
         OpenPVSignal:refers_to_concomitant_drug :alfacalcidol ,
                                                 :loperamide ,
                                                 :prednisolone ,
                                                 :rabeprazole ,
                                                 :sulfamethaxazole ,
                                                 :tacrolimus ,
                                                 :trimethoprim ,
                                                 :warfarin ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_5 ;
         OpenPVSignal:time_to_onset :TTO5 ;
         OpenPVSignal:has_reporter_type "study" ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                               :colitis_ischaemic ,
                                               :ischaemiaPeripheral ,
                                               :mesentericIschaemia ,
                                               :obstipation ,
                                               :thromboembolicEvent ,
                                               :woundHealingDelayed ,
                                               :woundInfection ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_6 ;
         OpenPVSignal:time_to_onset :TTO6 ;
         OpenPVSignal:has_reporter_type "study" ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :bowelIschaemia ,
                                               :veinThrombosisMesenteric ;
         OpenPVSignal:refers_to_concomitant_drug :indacaterol ,
                                                 :lercanidipine ,
                                                 :olmesartan ,
                                                 :salbutamol ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_7 ;
         OpenPVSignal:refers_to_secondary_suspect_drug :omeprazole ;
         OpenPVSignal:refers_to_outcome_after_action "recovering" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :bowelIschaemia ,
                                               :gastrointestinalNecrosis ,
                                               :intestinalIschaemia ,
                                               :necrosisBowel ;
         OpenPVSignal:refers_to_concomitant_drug :levothyroxine ,
                                                 :zoledronicAcid ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_8 ;
         OpenPVSignal:refers_to_secondary_suspect_drug :docetaxel ;
         OpenPVSignal:time_to_onset :TTO8 ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :intestinalInfarction ;
         OpenPVSignal:refers_to_concomitant_drug :lansoprazole ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :nintedanib ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_9 ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Free_text_reporting_element ;
                     OpenPVSignal:has_content """The drug-ADR combination of nintedanib-colitis was identified as a statistical signal during a screening of VigiBase, the WHO global database of individual case safety reports, performed in December 2018. The original case series included 25 cases which, upon review, described either different specific types of colitis, such as ischaemic or inflammatory, or were unspecified. Given that nintedanib acts upon the VEGF-receptor, a decision was taken to explore the association between nintedanib and the more specific clinical concept of “ischaemic colitis”.
One case with the original MedDRA Preferred Term (PT) “colitis” was considered to have information sufficient to be considered as “ischaemic colitis” (colonscopy results were provided). Subsequent exploration within VigiBase used the MedDRA Standardised Medical Query (SMQ), “ischaemic colitis (narrow)”. Nine additional cases were identified through this search strategy. The final case series consists of 10 cases: five reporting colitis ischaemic, two reporting intestinal ischaemia, one with both colitis ischemic and intestinal ischaemia, one intestinal infarction and one colitis. Illustrative case report
A 56-year-old female with a medical history of bronchial carcinoma and hypothyroidism. Therapy for bronchial carcinoma was initiated with nintedanib at 400 mg per day, and the patient was treated for 20 days. Twenty-five days after initiation of nintedanib, the patient experienced intestinal ischemia and gastrointestinal necrosis. She underwent surgical resection of the descending portion of the large intestine. Pathology revealed: “from the colon descendens, sigmoideum and upper rectum with intense and distinct ischemic necrosis of gut wall, inclusion of max. 2.3 cm polyp, without evidence of vital mucosa. Beside a 0.9 cm tubular adenoma with slight intraepithelial neoplasia (low- grade adenoma following WHO-classification)”.
Transmural hemorrhagic necrosis (reaching out up
to the resection area) of gut wall without inflammation, as appropriate for ischemia. Tumour- free resection of vessels and gut sections. The patient was subsequently initiated on docetaxel about one month after the event of gastrointestinal ischaemia.


Case series
Of the 10 reports in the case series, there was a predominance of males: seven reports compared to reports for females (table 2). Ages ranged between 53 and 78; age was not given in one report.
Reports originated from five countries (one country in the Americas, three in Europe, one in Asia). Time to onset ranged from three days to five months. In seven cases, the indication for use of nintedanib was idiopathic pulmonary fibrosis; in the three other cases, non-small cell lung cancer, bronchial carcinoma and glioblastoma. Diagnostic results were given in three cases (6, 8, and 10). Fatal outcomes were reported in four cases. Very limited information regarding the individual cases was available for most cases given that narratives had not been entered into VigiBase. Potential confounding factors/risk factors for ischaemic colitis was advanced age for many of the cases, concomitant use of corticosteroids in two cases (1
 
and 5) and the medical history of hyperlipidaemia in two cases (2 and 5).""" ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Reports_with_idiopathic_pulmonary_fibrosis_as_indication
:Reports_with_idiopathic_pulmonary_fibrosis_as_indication rdf:type owl:NamedIndividual ,
                                                                   OpenPVSignal:Reports_group ;
                                                          OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
                                                          OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                          OpenPVSignal:has_count 7 ;
                                                          rdfs:label "reports with idiopathic pulmonary fibrosis as indication" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Response_from_Boehringer_Ingelheim_AB
:Response_from_Boehringer_Ingelheim_AB rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                                       OpenPVSignal:refers_to_pharmacovigilance_signal_report :Nintedanib_and_ischaemic__colitis ;
                                       OpenPVSignal:refers_to_signal :pvSignal ;
                                       OpenPVSignal:has_content """The opportunity to comment on the signal of ‘ischaemic colitis’ for nintedanib identified by the Uppsala Monitoring Center (UMC) is acknowledged.


Nintedanib is authorised in 2 indications:
•	treatment of Idiopathic Pulmonary Fibrosis (IPF) and to slow disease progression (Ofev)
•	treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy (Vargatef)
In the indication IPF, nintedanib is administered as monotherapy (starting dose 150 mg bid). In the indication NSCLC nintedanib is administered in combination with docetaxel (starting dose of 200 mg bid). The dose of nintedanib can be reduced for the management of adverse reactions.
Diarrhoea, vomiting, nausea, abdominal pain, pancreatitis and bleeding are included in the list of ADRs of nintedanib. Diarrhoea and bleeding are
 


important identified risks. For Vargatef perforation, mucositis and venous thromboembolism (VTE) are also ADRs. Perforation is an important identified risk. Arterial thromboembolism is an important potential risk of nintedanib and perforation and VTE are important potential risks for Ofev. These conditions are regularly monitored.
Stomatitis, diarrhoea, nausea, vomiting, constipation as well as enterocolitis, colitis, ischaemic colitis, and neutropenic enterocolitis are known ADRs of docetaxel.
The signal of ‘colitis’ has been evaluated for nintedanib with DLP 15 Oct 2018 based on HLT ‘colitis, excluding infective’. In the next version of the EU SmPC ‘colitis’ will be included as ADR of nintedanib.
In order to appropriately address all comments by the UMC, it has been decided to evaluate data from all sources with regard to ischaemic colitis under treatment with nintedanib.""" ;
                                       rdfs:label "Response from Boehringer Ingelheim AB" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Summary_content
:Summary_content rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Summary ;
                 OpenPVSignal:has_content "Nintedanib is a small molecule protein kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis, a rare and progressive disease with a median survival of only several years after diagnosis. Statistical screening of VigiBase, the WHO global database of individual case safety reports, identified disproportional reporting of the MedDRA Preferred Term (PT) “colitis” with nintedanib. Review of published literature and further exploration allowed for refinement of the signal from the non-specific term of “colitis” to the more specific clinical scenario of ischaemic colitis. A number of Bradford Hill criteria, including strength of association, specificity, consistency, analogy and plausibility, are discussed to support the hypothesis of a causal relationship between nintedanib and ischaemic colitis. Communication of this signal is considered warranted, as early identification of ischaemia may prevent progression to the serious, life-threatening event of gastrointestinal perforation. Given that the most commonly occurring gastrointestinal adverse reaction for nintedanib is diarrhoea, which can be a symptom of ischaemic colitis, it could be important to inform health care providers to rule out ischaemia prior to the recommended symptomatic treatment of diarrhoea with loperamide." ;
                 rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO1
:TTO1 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "days" ;
      <http://www.w3.org/2006/time#numericPosition> 15 ;
      rdfs:label "TTO1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO10
:TTO10 rdf:type owl:NamedIndividual ,
                <http://www.w3.org/2006/time#DurationDescription> ;
       <http://www.w3.org/2006/time#nominalPosition> "days" ;
       <http://www.w3.org/2006/time#numericPosition> 9 ;
       rdfs:label "TTO10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO2
:TTO2 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "days" ;
      <http://www.w3.org/2006/time#numericPosition> 3 ;
      rdfs:label "TTO2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO3
:TTO3 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "months" ;
      <http://www.w3.org/2006/time#numericPosition> 4 ;
      rdfs:label "TTO3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO5
:TTO5 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "months" ;
      <http://www.w3.org/2006/time#numericPosition> 5 ;
      rdfs:label "TTO5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO6
:TTO6 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "days" ;
      <http://www.w3.org/2006/time#numericPosition> 27 ;
      rdfs:label "TTO6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#TTO8
:TTO8 rdf:type owl:NamedIndividual ,
               <http://www.w3.org/2006/time#DurationDescription> ;
      <http://www.w3.org/2006/time#nominalPosition> "days" ;
      <http://www.w3.org/2006/time#numericPosition> 25 ;
      rdfs:label "TTO8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Uppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    prov:Organization ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_1
:Usage_1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_dosage :Dosage_1 ,
                                       :Dosage_1b ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_10
:Usage_10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug_Usage ;
          OpenPVSignal:concerns_indication_for_use :non-smallCellLungCancer ;
          OpenPVSignal:refers_to_dosage :Dosage_10 ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          rdfs:label "Usage 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_2
:Usage_2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_dosage :Dosage_2 ,
                                       :Dosage_2b ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_3
:Usage_3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_dosage :Dosage_3 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_4
:Usage_4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_dosage :Dosage_4 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_5
:Usage_5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_dosage :Dosage_5 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_6
:Usage_6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :glioblastoma ;
         OpenPVSignal:refers_to_dosage :Dosage_6 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_7
:Usage_7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :fibrosisLung ;
         OpenPVSignal:refers_to_dosage :Dosage_7 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 7" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_8
:Usage_8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :bronchialCarcinoma ;
         OpenPVSignal:refers_to_dosage :Dosage_8 ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 8" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_9
:Usage_9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug_Usage ;
         OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ;
         OpenPVSignal:refers_to_drug :nintedanib ;
         rdfs:label "Usage 9" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Usage_of_Nintedanib
:Usage_of_Nintedanib rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug_Usage ;
                     OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ,
                                                              :non-smallCellLungCancer ;
                     OpenPVSignal:refers_to_drug :nintedanib ;
                     rdfs:label "Usage of Nintedanib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Warning_information_with_nintedanib
:Warning_information_with_nintedanib rdf:type owl:NamedIndividual ,
                                              OpenPVSignal:Warning_Information ;
                                     OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                                           :diarrhoea ,
                                                                           :gastrointestinalPerforation ,
                                                                           :nausea ,
                                                                           :pancreatitis ;
                                     OpenPVSignal:refers_to_drug :nintedanib ;
                                     OpenPVSignal:has_content """Product labelling for nintedanib includes warnings
for diarrhoea and gastrointestinal perforation in
section 4.4 of the Summary of Product
Characteristics. There is also information regarding
management options for serious cases of diarrhoea
including hydration, anti-diarrhoeal products, and
dose reduction and information regarding potential
risk factors for gastrointestinal perforation, such as
previous abdominal surgery or peptic ulceration,
and diverticular disease and concomitant use of
corticosteroids or NSAIDs. Included in the list of
ADRs in section 4.8 are nausea, vomiting,
diarrhoea, abdominal pain and pancreatitis.
Within the risk management plan were the
identified risks of diarrhoea and liver function
abnormalities as important identified risks and
“perforation” as an important potential risk; there
were no planned post-authorisation safety studies
to further characterise any risks for the
gastrointestinal system."""^^xsd:string ;
                                     rdfs:label "Warning information with nintedanib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#abdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R10.9" ;
               OpenPVSignal:has_MedDRA_code 10000081 ;
               OpenPVSignal:has_MedDRA_prefered_term "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#abnormalLossOfWeight
:abnormalLossOfWeight rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "R63.4" ;
                      OpenPVSignal:has_MedDRA_code 10000159 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Abnormal loss of weight" ;
                      rdfs:label "abnormal loss of weight" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#acetylcysteine
:acetylcysteine rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "R05CB01" ,
                                          "S01XA08" ,
                                          "V03AB23" ;
                rdfs:label "acetylcysteine" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#acetylsalicylicAcid
:acetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug ;
                     OpenPVSignal:has_ATC_code "A01AD05" ,
                                               "B01AC06" ,
                                               "B01AC56" ,
                                               "C10BX01" ,
                                               "C10BX02" ,
                                               "C10BX04" ,
                                               "C10BX05" ,
                                               "C10BX06" ,
                                               "C10BX08" ,
                                               "M01BA03" ,
                                               "N02BA01" ,
                                               "N02BA51" ,
                                               "N02BA71" ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#acuteMyocardialIschaemia
:acuteMyocardialIschaemia rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "I21.9" ;
                          OpenPVSignal:has_MedDRA_code 10028600 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Myocardial ischaemia" ;
                          rdfs:label "acute myocardial ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#aflibercept
:aflibercept rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L01XX44" ,
                                       "S01LA05" ;
             rdfs:label "aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#alfacalcidol
:alfacalcidol rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A11CC03" ,
                                        "M05BB06" ;
              rdfs:label "alfacalcidiol" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#anorexia
:anorexia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R63.0" ;
          OpenPVSignal:has_MedDRA_code 10002646 ;
          OpenPVSignal:has_MedDRA_prefered_term "Anorexia" ;
          rdfs:label "Anorexia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ascorbicAcid
:ascorbicAcid rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A11GA01" ;
              rdfs:label "ascorbicAcid" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#atorvastatin
:atorvastatin rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "C10AA05" ,
                                        "C10BA05" ,
                                        "C10BX03" ,
                                        "C10BX06" ,
                                        "C10BX08" ,
                                        "C10BX11" ;
              rdfs:label "atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#bevacizumab
:bevacizumab rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L01XC07" ;
             rdfs:label "bevacizumab" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#bevacizumabAndIntestinalischaemia-IC025
:bevacizumabAndIntestinalischaemia-IC025 rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                         OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                         OpenPVSignal:refers_to_drug :bevacizumab ;
                                         OpenPVSignal:has_value 2.23 ;
                                         rdfs:label "bevacizumab and intestinal ischaemia-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#bleeding
:bleeding rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "D69.9" ;
          OpenPVSignal:has_MedDRA_code 10055798 ;
          OpenPVSignal:has_MedDRA_prefered_term "Haemorrhage" ;
          rdfs:label "bleeding" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#bowelIschaemia
:bowelIschaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "K55.9" ;
                OpenPVSignal:has_MedDRA_code 10022680 ;
                OpenPVSignal:has_MedDRA_prefered_term "Intestinal ischaemia" ;
                rdfs:label "bowel ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#bronchialCarcinoma
:bronchialCarcinoma rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Indication ;
                    OpenPVSignal:has_ICD_code "C34.90" ;
                    OpenPVSignal:has_MedDRA_code 10006417 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Bronchial carcinoma" ;
                    rdfs:label "bronchial carcinoma" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#colitis
:colitis rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "K52.9" ;
         OpenPVSignal:has_MedDRA_code 10009887 ;
         OpenPVSignal:has_MedDRA_prefered_term "Colitis" ;
         rdfs:label "colitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#colitisDiarrhoeaVomiting
:colitisDiarrhoeaVomiting rdf:type owl:NamedIndividual ;
                          rdfs:label "colitisDiarrhoeaVomiting" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#colitis_ischaemic
:colitis_ischaemic rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "K55.9" ;
                   OpenPVSignal:has_MedDRA_code 10009895 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Colitis ischaemic" ;
                   rdfs:label "colitis ischaemic" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#confounders
:confounders rdf:type owl:NamedIndividual ,
                      obo:OAE_0001182 ;
             OpenPVSignal:refers_to_class :corticosteroids ;
             OpenPVSignal:has_content """Potential confounding factors/risk factors for ischaemic colitis was advanced age for many of the cases, concomitant use of corticosteroids in two cases (1
 and 5) and the medical history of hyperlipidaemia in two cases (2 and 5).""" ;
             rdfs:label "confounders" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#corticosteroids
:corticosteroids rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Potential_Confounder ;
                 OpenPVSignal:has_ATC_code "H02" ;
                 rdfs:label "corticosteroids" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#decreasedAppetite
:decreasedAppetite rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "R63.0" ;
                   OpenPVSignal:has_MedDRA_code 10061428 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Decreased appetite" ;
                   rdfs:label "decreased appetite" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#diarrhoea
:diarrhoea rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R19.7" ;
           OpenPVSignal:has_MedDRA_code 10012735 ;
           OpenPVSignal:has_MedDRA_prefered_term "Diarrhoea" ;
           rdfs:label "diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#dimemorfan
:dimemorfan rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R05DA11" ;
            rdfs:label "dimemorfan" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#docetaxel
:docetaxel rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01CD02" ;
           rdfs:label "docetaxel" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#dsf
:dsf rdf:type owl:NamedIndividual ,
              obo:OAE_0001125 ;
     OpenPVSignal:refers_to_adverse_effect :diarrhoea ;
     mp:references :Ref.14 ;
     OpenPVSignal:has_content """A small study of 10 patients aimed to examine the underlying pathophysiologic 
mechanism of diarrhoea. Sigmoidoscopy revealed no evidence of ischaemia in any of the 10 subjects; however, gastroduodenoscopy revealed mucosal abnormalities in 8 patients.14""" ;
     rdfs:label "Study of pathophysiologic mechanism of diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#fd
:fd rdf:type owl:NamedIndividual ,
             OpenPVSignal:Free_text_reporting_element ;
    OpenPVSignal:is_part_of :Introduction_content ;
    OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
    mp:references :Ref.2 ;
    OpenPVSignal:has_content "Ischaemic colitis is a condition caused by insufficient blood flow to the large intestine which results in mucosal ulceration, inflammation and haemorrhage. Causes can be either physiological (hypotension, secondary to embolus/thrombosis) or iatrogenic (secondary to medicines, surgery). Ischaemic colitis clinically manifests with diarrhoea, colicky abdominal pain, and rectal bleeding. It can be difficult for clinicians to differentiate ischaemic colitis from infective and inflammatory colitis. With its high mortality rate, patients with ischaemic colitis should be recognised quickly, as colonoscopic evaluation is recommended within 48 hours of symptom onset. Colonoscopy can distinguish those cases that may be treated with conservative management from those that require emergency resection. The complications which can arise from ischaemic colitis include obstruction, necrosis, and perforation.2" ;
    rdfs:label "pathophysiology of ischaemic colitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#fdsd
:fdsd rdf:type owl:NamedIndividual ,
               OpenPVSignal:Case_Report_Information ;
      OpenPVSignal:refers_to_patient :Patient10 ;
      OpenPVSignal:has_content "Serious. Clinical trial patient. Died, cause of death “respiratory failure” Medical history: Idiopathic cardiomyopathy Bronchial disorder Insomnia Pain Smoker Alcohol abuse Patient experienced diarrhoea and vomiting which required hospitalisation 10 days after initiation of drug. CT scan of abdomen on day of admission with probably stenosis lesion of the sigmoid colon and proximal colonic dilation and loops of small bowel. Colonoscopy 11 days after discontinuation of drug revealed ischemic colitis. Repeat CT 16 days after discontinuation revealed no evidence of obstruction. Investigator considered that there is a causal relationship between the drug and GI symptoms and signs." ;
      rdfs:label "Case Info 10" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#fibrosisLung
:fibrosisLung rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "J84.10" ;
              OpenPVSignal:has_MedDRA_code 10025088 ;
              OpenPVSignal:has_MedDRA_prefered_term "Lung fibrosis" ;
              rdfs:label "Lung fibrosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#fluvastatin
:fluvastatin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C10AA04" ;
             rdfs:label "fluvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#gastrointestinalNecrosis
:gastrointestinalNecrosis rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "K55.30" ;
                          OpenPVSignal:has_MedDRA_code 10028856 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Necrosis bowel" ;
                          rdfs:label "Necrosis bowel" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#gastrointestinalPerforation
:gastrointestinalPerforation rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_ICD_code "K63.1" ;
                             OpenPVSignal:has_MedDRA_code 10018001 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal perforation" ;
                             rdfs:label "gastrointestinal perforation" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#glioblastoma
:glioblastoma rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Indication ;
              OpenPVSignal:has_ICD_code "C71.0" ;
              OpenPVSignal:has_MedDRA_code 10018336 ;
              OpenPVSignal:has_MedDRA_prefered_term "Glioblastoma" ;
              rdfs:label "glioblastoma" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#glycerylTrinitrate
:glycerylTrinitrate rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "C01DA02" ;
                    rdfs:label "glycerylTrinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#hyperlipidemia
:hyperlipidemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Potential_Confounder ;
                OpenPVSignal:has_ICD_code "E78.5" ;
                OpenPVSignal:has_MedDRA_code 10062060 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperlipidaemia" ;
                rdfs:label "hyperlipidaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#hypoxia
:hypoxia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R09.02" ;
         OpenPVSignal:has_MedDRA_code 10021143 ;
         OpenPVSignal:has_MedDRA_prefered_term "Hypoxia" ;
         rdfs:label "hypoxia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#idiopathicPulmonaryFibrosis
:idiopathicPulmonaryFibrosis rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ,
                                      OpenPVSignal:Indication ;
                             OpenPVSignal:has_ICD_code "J84.112" ;
                             OpenPVSignal:has_MedDRA_code 10021240 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Idiopathic pulmonary fibrosis" ;
                             rdfs:label "idiopathic pulmonary fibrosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#indacaterol
:indacaterol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "R03AC18" ,
                                       "R03AL04" ;
             rdfs:label "indacaterol" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#insulin
:insulin rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "A10AD01" ;
         rdfs:label "insulin" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#intestinalHemorrhage
:intestinalHemorrhage rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "K92.2" ;
                      OpenPVSignal:has_MedDRA_code 10059175 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Intestinal haemorrhage" ;
                      rdfs:label "intestinal hemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#intestinalInfarction
:intestinalInfarction rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "K55.069" ;
                      OpenPVSignal:has_MedDRA_code 10022657 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Intestinal infarction" ;
                      rdfs:label "intestinal infarction" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#intestinalIschaemia
:intestinalIschaemia rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "K55.9" ;
                     OpenPVSignal:has_MedDRA_code 10022680 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Intestinal ischaemia" ;
                     rdfs:label "intestinal ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#intestinal_perforation
:intestinal_perforation rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "K63.1" ;
                        OpenPVSignal:has_MedDRA_code 10023804 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Large intestine perforation" ;
                        rdfs:label "large intestine perforation" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ipratropium
:ipratropium rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "R01AX03" ,
                                       "R03AL01" ,
                                       "R03AL02" ,
                                       "R03BB01" ;
             rdfs:label "ipratropium" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#irbesartan
:irbesartan rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09CA04" ,
                                      "C09DA04" ,
                                      "C09DB05" ;
            rdfs:label "irbesartan" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemiaPeripheral
:ischaemiaPeripheral rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "I73.9" ;
                     OpenPVSignal:has_MedDRA_code 10034576 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Peripheral ischaemia" ;
                     rdfs:label "ischaemia peripheral" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndaflibercept-IC025
:ischaemicColitisAndaflibercept-IC025 rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                      OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                      OpenPVSignal:refers_to_drug :aflibercept ;
                                      OpenPVSignal:has_value 0.62 ;
                                      rdfs:label "aflibercep and ischaemic colitis-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndbevacizumab-IC025
:ischaemicColitisAndbevacizumab-IC025 rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                      OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                      OpenPVSignal:refers_to_drug :bevacizumab ;
                                      OpenPVSignal:has_value 2.24 ;
                                      rdfs:label "bevacizumab and ischaemic colitis-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndmidostaurin-IC025
:ischaemicColitisAndmidostaurin-IC025 rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                      OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                      OpenPVSignal:refers_to_drug :midostaurin ;
                                      OpenPVSignal:has_value 0.38 ;
                                      rdfs:label "midostaurin and intestinal ischaemia-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndranibizumab-IC025
:ischaemicColitisAndranibizumab-IC025 rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                      OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                      OpenPVSignal:refers_to_drug :ranibizumab ;
                                      OpenPVSignal:has_value 0.36 ;
                                      rdfs:label "ranibizumab and intestinal ischaemia-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndsorafenib-IC025
:ischaemicColitisAndsorafenib-IC025 rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                    OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                                    OpenPVSignal:refers_to_drug :sorafenib ;
                                    OpenPVSignal:has_value 0.18 ;
                                    rdfs:label "sorafenib and ischaemic colitis-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischaemicColitisAndsunitinib-IC025
:ischaemicColitisAndsunitinib-IC025 rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                    OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                    OpenPVSignal:refers_to_drug :sunitinib ;
                                    OpenPVSignal:has_value 0.22 ;
                                    rdfs:label "sunitinib and intestinal ischaemia-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ischemia
:ischemia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10061255 ;
          OpenPVSignal:has_MedDRA_prefered_term "Ischaemia" ;
          rdfs:label "ischemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#lansoprazole
:lansoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC03" ,
                                        "A02BC53" ,
                                        "A02BD02" ,
                                        "A02BD03" ,
                                        "A02BD07" ,
                                        "A02BD09" ,
                                        "A02BD10" ;
              rdfs:label "lansoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#lercanidipine
:lercanidipine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "C08CA13" ,
                                         "C09BB02" ,
                                         "C09DB08" ;
               rdfs:label "lercanidipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#levothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#loperamide
:loperamide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A07DA03" ,
                                      "A07DA05" ,
                                      "A07DA53" ;
            rdfs:label "loperamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#lormetazepam
:lormetazepam rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N05CD06" ;
              rdfs:label "lormetazepam" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#mesentericIschaemia
:mesentericIschaemia rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "K55.9" ;
                     OpenPVSignal:has_MedDRA_code 10022680 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Intestinal ischaemia" ;
                     rdfs:label "mesenteric ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#metamizole
:metamizole rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N02BB02" ,
                                      "N02BB52" ,
                                      "N02BB72" ;
            rdfs:label "metamizole" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#midostaurin
:midostaurin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L01EX10" ;
             rdfs:label "midostaurin" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#minodronicAcid
:minodronicAcid rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "M05BA" ;
                rdfs:label "minodronicAcid" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#mucositis
:mucositis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "K92.81" ;
           OpenPVSignal:has_MedDRA_code 10028116 ;
           OpenPVSignal:has_MedDRA_prefered_term "Mucosal inflammation" ;
           rdfs:label "mucositis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#nausea
:nausea rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R11" ;
        OpenPVSignal:has_MedDRA_code 10028813 ;
        OpenPVSignal:has_MedDRA_prefered_term "Nausea" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#necrosisBowel
:necrosisBowel rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "K55.30" ;
               OpenPVSignal:has_MedDRA_code 10017982 ;
               OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal necrosis" ;
               rdfs:label "Gastrointestinal necrosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#nintedanib
:nintedanib rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:concerns_indication_for_use :idiopathicPulmonaryFibrosis ,
                                                     :non-smallCellLungCancer ;
            OpenPVSignal:has_mechanism :Biologic_plausibility_for_nintedanib_and_ischaemic_colitis ,
                                       :Epithelial_hypoxia_in_diarrhoea_pathobiology ,
                                       :Mechanism_of_nintedanib ;
            OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                  :bleeding ,
                                                  :diarrhoea ,
                                                  :nausea ,
                                                  :pancreatitis ,
                                                  :vomiting ;
            OpenPVSignal:has_ATC_code "L01XE31" ;
            rdfs:label "nintedanib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#nintedanib_and_gastrointestinal_necrosis-IC025
:nintedanib_and_gastrointestinal_necrosis-IC025 rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                                OpenPVSignal:refers_to_adverse_effect :necrosisBowel ;
                                                OpenPVSignal:refers_to_drug :nintedanib ;
                                                OpenPVSignal:has_value -1.50 ;
                                                rdfs:label "nintedanib and gastrointestinal necrosis-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#nintedanib_and_intestinal_haemorrhage-IC025
:nintedanib_and_intestinal_haemorrhage-IC025 rdf:type owl:NamedIndividual ,
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                             OpenPVSignal:refers_to_adverse_effect :intestinalHemorrhage ;
                                             OpenPVSignal:refers_to_drug :nintedanib ;
                                             OpenPVSignal:has_value -0.34 ;
                                             rdfs:label "nintedanib and intestinal haemorrhage-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#nintedanib_and_intestinal_perforation-IC025
:nintedanib_and_intestinal_perforation-IC025 rdf:type owl:NamedIndividual ,
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                             OpenPVSignal:refers_to_adverse_effect :intestinal_perforation ;
                                             OpenPVSignal:refers_to_drug :nintedanib ;
                                             OpenPVSignal:has_value 1.48 ;
                                             rdfs:label "nintedanib and large intestine perforation-IC025" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#non-smallCellLungCancer
:non-smallCellLungCancer rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Indication ;
                         OpenPVSignal:has_ICD_code "C34.90" ;
                         OpenPVSignal:has_MedDRA_code 10061873 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Non-small cell lung cancer" ;
                         rdfs:label "non-small cell lung cancer" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#obstipation
:obstipation rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "K59.00" ;
             OpenPVSignal:has_MedDRA_code 10029932 ;
             OpenPVSignal:has_MedDRA_prefered_term "Obstipation" ;
             rdfs:label "Obstipation" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#olmesartan
:olmesartan rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09CA08" ,
                                      "C09DA08" ,
                                      "C09DB02" ,
                                      "C09DX03" ;
            rdfs:label "olmesartan" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#omeprazole
:omeprazole rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BC01" ,
                                      "A02BD01" ,
                                      "A02BD05" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#overallReportsInVigibase
:overallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:refers_to_drug :nintedanib ;
                          OpenPVSignal:time_to_onset :Overall_Time_to_onset ;
                          OpenPVSignal:has_count 10 ;
                          OpenPVSignal:has_count_of_men 7 ;
                          OpenPVSignal:has_count_of_women 3 ;
                          OpenPVSignal:has_max_age "78.0"^^xsd:float ;
                          OpenPVSignal:has_min_age "53.0"^^xsd:float ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#pancreatitis
:pancreatitis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "K85" ;
              OpenPVSignal:has_MedDRA_code 10033645 ;
              OpenPVSignal:has_MedDRA_prefered_term "Pancreatitis" ;
              rdfs:label "pancreatitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#pantothenicAcid
:pantothenicAcid rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "A11HA31" ,
                                           "D03AX04" ;
                 rdfs:label "pantothenic acid" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#pneumoniaBacterial
:pneumoniaBacterial rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "J15.9" ;
                    OpenPVSignal:has_MedDRA_code 10060946 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Pneumonia bacterial" ;
                    rdfs:label "pneumonia bacterial" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#prednisolone
:prednisolone rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A01AC54" ,
                                        "A07EA01" ,
                                        "C05AA04" ,
                                        "D07AA03" ,
                                        "D07BA01" ,
                                        "D07CA03" ,
                                        "D07XA02" ,
                                        "H02AB06" ,
                                        "R01AD02" ,
                                        "R01AD52" ,
                                        "S01BA04" ,
                                        "S01BB02" ,
                                        "S01CA02" ,
                                        "S01CB02" ,
                                        "S02BA03" ,
                                        "S02CA01" ,
                                        "S03BA02" ,
                                        "S03CA02" ,
                                        "V03AB05" ;
              rdfs:label "prednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :Conclusion_content ,
                                                   :Discussion_content ,
                                                   :Idiopathic_pulmonary_fibrosis_pathophysiology ,
                                                   :Introduction_content ,
                                                   :Reports_in_Vigibase ,
                                                   :Summary_content ,
                                                   :fd ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report10 ,
                                                              :Report2 ,
                                                              :Report3 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report8 ,
                                                              :Report9 ;
          OpenPVSignal:is_supported_by_statistical_entity :NintedanibAndColitisischaemic-IC ,
                                                          :NintedanibAndColitisischaemic-IC025 ,
                                                          :NintedanibAndColitisischaemic-Nexpected ,
                                                          :NintedanibAndColitisischaemic-Nobserved ,
                                                          :NintedanibAndIntestinalinfarction-IC ,
                                                          :NintedanibAndIntestinalinfarction-IC025 ,
                                                          :NintedanibAndIntestinalinfarction-Nexpected ,
                                                          :NintedanibAndIntestinalinfarction-Nobserved ,
                                                          :NintedanibAndIntestinalischaemia-IC ,
                                                          :NintedanibAndIntestinalischaemia-IC025 ,
                                                          :NintedanibAndIntestinalischaemia-Nexpected ,
                                                          :NintedanibAndIntestinalischaemia-Nobserved ,
                                                          :NintedanibAndIschaemicColitisSMQ-IC ,
                                                          :NintedanibAndcolitis-IC ,
                                                          :NintedanibAndcolitis-IC50 ,
                                                          :NintedanibAndcolitis-Nexpected ,
                                                          :NintedanibAndcolitis-Nobserved ,
                                                          :Nintedanib_and_Ischaemic_colitis_SMQ-IC025 ,
                                                          :Reports_with_idiopathic_pulmonary_fibrosis_as_indication ,
                                                          :bevacizumabAndIntestinalischaemia-IC025 ,
                                                          :ischaemicColitisAndaflibercept-IC025 ,
                                                          :ischaemicColitisAndbevacizumab-IC025 ,
                                                          :ischaemicColitisAndmidostaurin-IC025 ,
                                                          :ischaemicColitisAndranibizumab-IC025 ,
                                                          :ischaemicColitisAndsorafenib-IC025 ,
                                                          :ischaemicColitisAndsunitinib-IC025 ,
                                                          :nintedanib_and_gastrointestinal_necrosis-IC025 ,
                                                          :nintedanib_and_intestinal_haemorrhage-IC025 ,
                                                          :nintedanib_and_intestinal_perforation-IC025 ,
                                                          :overallReportsInVigibase ,
                                                          :reportsWithColitis ,
                                                          :reportsWithColitisIschaemic ,
                                                          :reportsWithColitisIschaemicAndIntestinalIschaemia ,
                                                          :reportsWithFatalOutcomes ,
                                                          :reportsWithIntestinalInfarction ,
                                                          :reportsWithIntestinalIschaemia ,
                                                          :reports_with_bronchial_carcinoma_as_indication ,
                                                          :reports_with_non_small_cell_lung_cancer_as_indication ;
          OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
          OpenPVSignal:refers_to_drug :nintedanib ;
          mp:supportedBy :Bradford_Hill_criteria ;
          mp:supportedByData :Bradford_Hill_criteria ,
                             :Case_reports_of_ischaemic_cilitis ,
                             :Epithelial_hypoxia_in_diarrhoea_pathobiology ,
                             :Labelling_for_anti-VEGF_agents ,
                             :Product_labelling_for_nintedanib ,
                             :Warning_information_with_nintedanib ,
                             :confounders ,
                             :dsf ;
          OpenPVSignal:initially_identified_on "01/12/2019" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#rabeprazole
:rabeprazole rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A02BC04" ,
                                       "A02BC54" ,
                                       "M01AA05" ,
                                       "M02AA03" ;
             rdfs:label "rabeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#ranibizumab
:ranibizumab rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "S01LA04" ;
             rdfs:label "ranibizumab" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#regorafenib
:regorafenib rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L01XE21" ;
             rdfs:label "regorafenib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithColitis
:reportsWithColitis rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                    OpenPVSignal:refers_to_adverse_effect :colitis ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports with colitis" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithColitisIschaemic
:reportsWithColitisIschaemic rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Reports_group ;
                             OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                             OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ;
                             OpenPVSignal:has_count 5 ;
                             OpenPVSignal:refers_to_database "WHO Vigibase" ;
                             rdfs:label "reports with colitis ischaemic" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithColitisIschaemicAndIntestinalIschaemia
:reportsWithColitisIschaemicAndIntestinalIschaemia rdf:type owl:NamedIndividual ,
                                                            OpenPVSignal:Reports_group ;
                                                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                   OpenPVSignal:refers_to_adverse_effect :colitis_ischaemic ,
                                                                                         :intestinalIschaemia ;
                                                   OpenPVSignal:has_count 1 ;
                                                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                   rdfs:label "reports with colitis ischaemic and intestinal ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithFatalOutcomes
:reportsWithFatalOutcomes rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                          OpenPVSignal:has_count 4 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          OpenPVSignal:refers_to_outcome_after_action "death" ;
                          rdfs:label "reports with fatal outcomes" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithIntestinalInfarction
:reportsWithIntestinalInfarction rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                 OpenPVSignal:refers_to_adverse_effect :intestinalInfarction ;
                                 OpenPVSignal:has_count 1 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports with intestinal infarction" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reportsWithIntestinalIschaemia
:reportsWithIntestinalIschaemia rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                OpenPVSignal:refers_to_adverse_effect :intestinalIschaemia ;
                                OpenPVSignal:has_count 2 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                rdfs:label "reports with intestinal ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reports_with_bronchial_carcinoma_as_indication
:reports_with_bronchial_carcinoma_as_indication rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Reports_group ;
                                                OpenPVSignal:concerns_indication_for_use :glioblastoma ;
                                                OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                OpenPVSignal:has_count 1 ;
                                                rdfs:label "reports with bronchial carcinoma as indication" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#reports_with_non_small_cell_lung_cancer_as_indication
:reports_with_non_small_cell_lung_cancer_as_indication rdf:type owl:NamedIndividual ,
                                                                OpenPVSignal:Reports_group ;
                                                       OpenPVSignal:concerns_indication_for_use :non-smallCellLungCancer ;
                                                       OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                       OpenPVSignal:has_count 1 ;
                                                       rdfs:label "reports with non small cell lung cancer as indication" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#respiratoryFailure
:respiratoryFailure rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "J96.00" ;
                    OpenPVSignal:has_MedDRA_code 10038695 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Respiratory failure" ;
                    rdfs:label "respiratory failure" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#salbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC02" ,
                                      "R03AK04" ,
                                      "R03AL02" ,
                                      "R03CC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#septicShock
:septicShock rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R65.21" ;
             OpenPVSignal:has_MedDRA_code 10040070 ;
             OpenPVSignal:has_MedDRA_prefered_term "Septic shock" ;
             rdfs:label "septic shock" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#sorafenib
:sorafenib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE05" ;
           rdfs:label "sorafenib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#sulfamethaxazole
:sulfamethaxazole rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "J01EE01" ;
                  rdfs:label "sulfamethaxazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#sunitinib
:sunitinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE04" ;
           rdfs:label "sunitinib" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#tacrolimus
:tacrolimus rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "D11AH01" ,
                                      "L04AD02" ;
            rdfs:label "tacrolimus" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#thromboembolicEvent
:thromboembolicEvent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "I74.9" ;
                     OpenPVSignal:has_MedDRA_code 10061169 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Embolism" ;
                     rdfs:label "thromboembolic event" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#torasemide
:torasemide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C03CA04" ;
            rdfs:label "torasemide" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#trichlormethiazide
:trichlormethiazide rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "C03AA06" ,
                                              "C03AB06" ,
                                              "C03EA02" ,
                                              "G01AE10" ;
                    rdfs:label "trichlormethiazide" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#trimethoprim
:trimethoprim rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "J01EA01" ,
                                        "J01EE01" ,
                                        "J01EE02" ,
                                        "J01EE03" ,
                                        "J01EE04" ,
                                        "J01EE05" ,
                                        "J01EE07" ;
              rdfs:label "trimethoprim" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#v
:v rdf:type owl:NamedIndividual ,
            OpenPVSignal:Case_Report_Information ;
   OpenPVSignal:refers_to_patient :Patient3 ;
   OpenPVSignal:has_content "50.5 kg, 161 cm" ;
   rdfs:label "Case Info 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#veinThrombosisMesenteric
:veinThrombosisMesenteric rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "K55.0" ;
                          OpenPVSignal:has_MedDRA_code 10027402 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Mesenteric vein thrombosis" ;
                          rdfs:label "vein thrombosis mesenteric" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#vomiting
:vomiting rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R11" ;
          OpenPVSignal:has_MedDRA_code 10047700 ;
          OpenPVSignal:has_MedDRA_prefered_term "Vomiting" ;
          rdfs:label "vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#vonoprazan
:vonoprazan rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BC08" ;
            rdfs:label "vonoprazan" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#warfarin
:warfarin rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "B01AA03" ;
          rdfs:label "warfarin" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#woundHealingDelayed
:woundHealingDelayed rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "T81.89XA" ;
                     OpenPVSignal:has_MedDRA_code 10021519 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Impaired healing" ;
                     rdfs:label "wound healing delayed" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#woundInfection
:woundInfection rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "L08.9" ;
                OpenPVSignal:has_MedDRA_code 10048038 ;
                OpenPVSignal:has_MedDRA_prefered_term "Wound infection" ;
                rdfs:label "wound infection" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#zoledronicAcid
:zoledronicAcid rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "M05BA08" ,
                                          "M05BB08" ;
                rdfs:label "zoledronic acid" .


###  http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ischaemic_colitis_(SMQ)
<http://purl.org/OpenPVSignal/Signals/2019_6_nintedanib_ischaemic_colitis.owl#Ischaemic_colitis_(SMQ)> rdf:type owl:NamedIndividual ,
                                                                                                                OpenPVSignal:Adverse_Effect ;
                                                                                                       OpenPVSignal:has_ICD_code "K55.9" ;
                                                                                                       OpenPVSignal:has_MedDRA_code 20000144 ;
                                                                                                       OpenPVSignal:has_MedDRA_prefered_term "Ischaemic colitis (SMQ)" ;
                                                                                                       rdfs:label "Ischaemic colitis (SMQ)" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
